SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining significant community attention as a key liquidity hub for the Base ecosystem, with investors closely watching upcoming product upgrades and potential expansion onto the Ethereum network. Sentiment remains heavily polarized, as bullish participants highlight strong volume and integration potential while bears caution against market volatility and potential downside in broader crypto conditions.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a major focus of community debate as traders weigh short-term volatility and market-wide bearish sentiment against strong network fundamentals, such as record institutional stablecoin volume and ongoing ETF discussions. While some investors are accumulating aggressively on dips, others are debating whether current price levels represent a bottom or a precursor to further downside amid a broader crypto-market correction.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X ETF

JNUG is currently seeing heightened trader interest as market participants digest a flurry of volatile macro updates, including ongoing geopolitical tensions in the Middle East and intensified central bank gold accumulation. Community discussion remains heavily focused on the potential for Fed policy shifts and renewed inflationary pressures, fueling speculative momentum in the leveraged junior mining sector.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure and trading near multi-year lows, sparking a divide between bulls who view the current price as a rare accumulation opportunity given the network's active institutional adoption and bulls who fear the project is losing market relevance. Community sentiment is deeply polarized, with many investors expressing frustration over recent losses while others advocate for dollar-cost averaging in anticipation of a long-term cyclical recovery.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is currently trending as a leading play in the real-world asset (RWA) tokenization space, with investors closely watching for potential regulatory progress from the Clarity Act to spark institutional adoption. Community members remain focused on the token's long-term potential as a bridge between traditional finance and blockchain, despite ongoing debates surrounding governance voting and the timeline for fee-switch implementation.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is experiencing significant community debate as discussions shift between its status as a high-risk meme asset and its comparison to other trending tokens within the Solana ecosystem. Investors are actively tracking whale activity and liquidity patterns while debating whether the current price action signals a potential breakout or a broader decline for this speculative asset.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is facing significant downward pressure and intense scrutiny from the community, driven by a volatile mix of insider buying, heavy short interest, and skepticism regarding the timing of management's clinical trial updates. Investors are actively debating the company's long-term potential as a 'pipeline-in-a-product' candidate for oncology and autoimmune conditions versus concerns about cash burn and a crowded therapeutic landscape.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is generating community interest as traders look for potential accumulation opportunities amid broader market expectations for upcoming regulatory clarity and increased ecosystem development. Discussions are split between high-conviction holders focused on staking rewards and those speculating on a technical breakout from the current base-building phase.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate whether the project represents a deep-value opportunity in collateralized payment infrastructure or a declining asset, with discussion dominated by the search for a bottom amidst extended price stagnation. While some community members maintain long-term conviction in the technology's utility and regulatory potential, many others are vocal about their frustration regarding management's perceived lack of transparency and the token's persistent downward trend.

DEGEN is a reward token for Farcaster users, born from meme culture. It features a unique tipping system that allows the community to reward high-quality content creators. DEGEN also powers the Degen Chain, one of the pioneering Layer 3s launched on Base. Known as the “Las Vegas of blockchains,” it provides a platform for building and using Degen apps, offering a space for fun, innovation, and community-driven experiences.

Degen

Degen is generating significant community buzz surrounding upcoming ecosystem expansions, including new app launches and ongoing token burn campaigns. Investors are actively debating the token's long-term utility and potential for a breakout, while closely monitoring treasury activity and developer updates.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of -31.52% and -93.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four ha...

Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday

Keros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Keros Therapeutics Inc

Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.34	--	--	N/A
Q1 '26	-$1.02	-$1.21	-18.30%	MISSED
Q4 '25	-$0.70	-$0.86	-23.36%	MISSED
Q3 '25	-$1.05	-$0.18	82.82%	BEAT
Q2 '25	-$1.11	-$0.76	31.52%	BEAT

KROSKeros Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest KROS News